AbbVie has announced a $10.9 billion deal to acquire Apogee Therapeutics, which will strengthen its immunology pipeline. The acquisition aims to address investor concerns about growth beyond the company’s successful Skyrizi and Rinvoq treatments.
Source: https://www.investors.com/news/technology/abbvie-apogee-therapeutics-acquisition-apogee-stock